Navigation Links
23andMe opens its API to developers
Date:9/14/2012

Mountain View, CA September 14, 2012 23andMe, the leading personal genetics company, today announced that it will open its application programming interface (API) to third-party developers, beginning September 17, 2012, following a presentation by Mike Polcari, the company's Director of Engineering, at the Quantified Self Conference in Palo Alto, Calif., on September 16th. 23andMe's open API is designed to allow authorized developers to build a broad range of new applications and tools for the 23andMe community generated from the company's data sets.

"Opening our API offers an immense opportunity for customers to do more with their DNA," stated 23andMe CEO and Co-Founder Anne Wojcicki. "While 23andMe has created a number of groundbreaking and innovative tools for our customer to explore their DNA, the API will open the door to the possibility of new web-based interactive tools to be developed by external groups."

23andMe's API will require individual-level consent for all data that may be referenced by third-party developers in their applications. Approved developers will receive an authentication key that provides secure access to the platform. Developers can apply to access 23andMe's API at https://api.23andme.com.

The Quantified Self Conference brings together technologists, designers, users, entrepreneurs, scientists, health professionals and media to discuss new ideas and collaboration tools that will advance self-tracking projects. "The Quantified Self movement has already expressed interest in an API for the 23andMe platform," added Mike Polcari, director of engineering at 23andMe. "We anticipate a comparable level of interest from the broader developer community for our early-access API program."

An ongoing service, 23andMe's Personal Genome Service provides a wealth of information about an individual's DNA and updates about new research. Customers can also choose to participate in the company's unique research programs. By completing online surveys, customers contribute directly to genetic research that can potentially lead to better understanding of and new treatments for a variety of health conditions. To learn more, visit www.23andMe.com.
'/>"/>

Contact: Jane E. Rubinstein
jrubinstein@rubenstein.com
212-843-8287
23andMe Inc.
Source:Eurekalert  

Related biology news :

1. 23andMe identifies 5 significant genetic associations for hypothyroidism
2. 23andMe contributes to genetic discoveries related to male pattern baldness
3. 3-D RNA modeling opens scientific doors
4. Press accreditation opens for World Series of Science
5. Understanding why some people have propensity to disease
6. Major osteoporosis meeting opens in São Paulo
7. Next-generation sequencing technology opens doors to discoveries
8. Media registration opens for Neuroscience 2012, worlds largest brain science meeting
9. Cell research opens new avenues in combating neurodegenerative diseases
10. OpenStax Colleges free textbooks will save students $1 million this fall
11. Compounds shown to thwart stubborn pathogens social propensity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
23andMe opens its API to developers
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... and sale of advanced technology solutions and products to ... announced the addition of new cohorts of PDX models ... models will expand Champions, product line in hepatocellular cancer, ... cancer, AML, and non-small cell lung cancer (including EGFR ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
Breaking Biology Technology: